Curcumin and endothelial function: Evidence and mechanisms of protective effects

Current Pharmaceutical Design

Volumn 23, Issue 17, 2017, Pages 2462-2473

  Karimian, Maryam S ^a   Pirro, Matteo ^b   Johnston, Thomas P ^c   Majeed, Muhammed ^d   Sahebkare, Amirhossein ^a,e,f  

^a MASHHAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b UNIVERSITY OF PERUGIA   (Italy)

^c UNIVERSITY OF MISSOURI KANSAS CITY   (United States)

^d SABINSA CORPORATION   (United States)

^e MASHHAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^f UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

Adhesion molecules; Curcumin; Endothelial function; Flow mediated vasodilation; Nitroglycerin mediated dilation; Pulse wave velocity

Indexed keywords

BEVACIZUMAB; BIOLOGICAL MARKER; CURCUMIN; HEME OXYGENASE 1; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERCELLULAR ADHESION MOLECULE 1; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE P38; PADGEM PROTEIN; POLYPHENOL; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 2; STAT3 PROTEIN; STRESS ACTIVATED PROTEIN KINASE; TUMOR NECROSIS FACTOR; VASCULAR CELL ADHESION MOLECULE 1; VASCULOTROPIN; ANGIOGENESIS INHIBITOR; NONSTEROID ANTIINFLAMMATORY AGENT;

AGING; ANTIANGIOGENIC ACTIVITY; ANTIHYPERTENSIVE ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ANTIMICROBIAL ACTIVITY; ANTINEOPLASTIC ACTIVITY; ANTIOXIDANT ACTIVITY; ANTIVIRAL ACTIVITY; APOPTOSIS; CANCER INHIBITION; CELL MIGRATION; DIET SUPPLEMENTATION; DRUG MECHANISM; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM CELL; HUMAN; MONOCYTE; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INDUCTION; PROTEIN SYNTHESIS INHIBITION; REVIEW; VASCULAR ENDOTHELIUM; WOUND HEALING; CARDIOVASCULAR DISEASE; DRUG EFFECT;

ANGIOGENESIS INHIBITORS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CARDIOVASCULAR DISEASES; CURCUMIN; ENDOTHELIUM, VASCULAR; HUMANS;

EID: 85017467271     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/1381612823666170222122822     Document Type: Review

References (178)

1. Flammer AJ, Anderson T, Celermajer DS, et al. The assessment of endothelial function: from research into clinical practice. Circulation 2012; 126: 753-67.
2. Raitakari OT, Celermajer DS. Flow-mediated dilatation. Br J Clin Pharmacol 2000; 50: 397-404.
3. Cooke JP, Rossitch E, Jr., Andon NA, Loscalzo J, Dzau VJ. Flow activates an endothelial potassium channel to release an endogenous nitrovasodilator. J Clin Invest 1991; 88: 1663-71.
4. Miura H, Wachtel RE, Liu Y, et al. Flow-induced dilation of human coronary arterioles: important role of Ca(2+)-activated K(+) channels. Circulation 2001; 103: 1992-8.
5. Olesen SP, Clapham DE, Davies PF. Haemodynamic shear stress activates a K+ current in vascular endothelial cells. Nature 1988; 331: 168-70.
6. Pohl U, Holtz J, Busse R, Bassenge E. Crucial role of endothelium in the vasodilator response to increased flow in vivo. Hypertension 1986; 8: 37-44.
7. Joannides R, Haefeli WE, Linder L, et al. Nitric oxide is responsible for flow-dependent dilatation of human peripheral conduit arteries in vivo. Circulation 1995; 91: 1314-9.
8. Corson MA, James NL, Latta SE, Nerem RM, Berk BC, Harrison DG. Phosphorylation of endothelial nitric oxide synthase in response to fluid shear stress. Circ Res 1996; 79: 984-91.
9. Xavier C. Methods of assessing endothelial function, vasodilation of interest by the intermediate flow. Cardiol Pract 2006; 8: 10-12.
10. Pries AR, Kuebler WM. Normal endothelium. Handb Exp Pharmacol 2006: 1-40.
11. Lum H, Roebuck KA. Oxidant stress and endothelial cell dysfunction. Am J Physiol Cell Physiol 2001; 280: C719-41.
12. Wolf MB, Baynes JW. The anti-cancer drug, doxorubicin, causes oxidant stress-induced endothelial dysfunction. Biochim Biophys Acta 2006; 1760: 267-71.
13. Grant DS, Williams TL, Zahaczewsky M, Dicker AP. Comparison of antiangiogenic activities using paclitaxel (taxol) and docetaxel (taxotere). Int J Cancer 2003; 104: 121-9.
14. Celermajer DS, Sorensen KE, Gooch VM, et al. Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet 1992; 340: 1111-5.
15. Sorensen KE, Celermajer DS, Spiegelhalter DJ, et al. Non-invasive measurement of human endothelium dependent arterial responses: accuracy and reproducibility. Br Heart J 1995; 74: 247-53.
16. Puissant C, Abraham P, Durand S, et al. Endothelial function: role, assessment and limits. J Mal Vasc 2014; 39: 47-56.
17. Uehata A, Lieberman EH, Gerhard MD, et al. Noninvasive assessment of endothelium-dependent flow-mediated dilation of the brachial artery. Vasc Med 1997; 2: 87-92.
18. Joannides R, Richard V, Haefeli WE, et al. Role of nitric oxide in the regulation of the mechanical properties of peripheral conduit arteries in humans. Hypertension 1997; 30: 1465-70.
19. Stadler RW, Karl WC, Lees RS. New methods for arterial diameter measurement from B-mode images. Ultrasound Med Biol 1996; 22: 25-34.
20. Inaba Y, Chen JA, Bergmann SR. Prediction of future cardiovascular outcomes by flow-mediated vasodilatation of brachial artery: a meta-analysis. Int J Cardiovasc Imaging 2010; 26: 631-40.
21. Harris RA, Nishiyama SK, Wray DW, Richardson RS. Ultrasound assessment of flow-mediated dilation. Hypertension 2010; 55: 1075-85.
22. Pirro M, Schillaci G, Romagno PF, et al. Influence of short-term rosuvastatin therapy on endothelial progenitor cells and endothelial function. J Cardiovasc Pharmacol Ther 2009; 14: 14-21.
23. Marchesi S, Lupattelli G, Lombardini R, et al. Effects of fenofibrate on endothelial function and cell adhesion molecules during post-prandial lipemia in hypertriglyceridemia. J Clin Pharm Ther 2003; 28: 419-24.
24. Maruhashi T, Soga J, Fujimura N, Idei N, et al. Nitroglycerineinduced vasodilation for assessment of vascular function: a comparison with flow-mediated vasodilation. Arterioscler Thromb Vasc Biol 2013; 33: 1401-8.
25. Ducharme A, Dupuis J, McNicoll S, Harel F, Tardif JC. Comparison of nitroglycerin lingual spray and sublingual tablet on time of onset and duration of brachial artery vasodilation in normal subjects. Am J Cardiol 1999; 84: 952-4, A8.
26. Raitakari OT, Seale JP, Celermajer DS. Impaired vascular responses to nitroglycerin in subjects with coronary atherosclerosis. Am J Cardiol 2001; 87: 217-9, A8.
27. Yun L, Xu R, Zhang L, et al. The role of microalbuminuria in arterial endothelial dysfunction in hypertensive patients with carotid plaques. Int Heart J 2014; 55: 153-9.
28. Castellon X, Bogdanova V. Chronic inflammatory diseases and endothelial dysfunction. Aging Dis 2016; 7: 81-9.
29. Pirro M, Schillaci G, Savarese G, et al. Low-grade systemic inflammation impairs arterial stiffness in newly diagnosed hypercholesterolaemia. Eur J Clin Invest 2004; 34: 335-41.
30. Pirro M, Schillaci G, Savarese G, et al. Attenuation of inflammation with short-term dietary intervention is associated with a reduction of arterial stiffness in subjects with hypercholesterolaemia. Eur J Cardiovasc Prev Rehabil 2004; 11: 497-502.
31. Pirro M, Schillaci G, Mannarino MR, et al. Circulating immature osteoprogenitor cells and arterial stiffening in postmenopausal osteoporosis. Nutr Metab Cardiovasc Dis 2011; 21: 636-42.
32. Pirro M, Schillaci G, Mannarino MR, et al. Effects of rosuvastatin on 3-nitrotyrosine and aortic stiffness in hypercholesterolemia. Nutr Metab Cardiovasc Dis 2007; 17: 436-41.
33. Schillaci G, Pirro M. C-reactive protein in hypertension: clinical significance and predictive value. Nutr Metab Cardiovasc Dis 2006; 16: 500-8.
34. O'Rourke MF, O'Brien C, Edelman ER. Arterial stiffening in perspective: Advances in physical and physiological science over centuries. Am J Hypertens 2016; 29: 785-91.
35. Sengupta PP, Pedrizzetti G, Kilner PJ, et al. Emerging trends in CV flow visualization. JACC Cardiovasc Imaging 2012; 5: 305-16.
36. Widlansky ME, Gokce N, Keaney JF, Jr., Vita JA. The clinical implications of endothelial dysfunction. J Am Coll Cardiol 2003; 42: 1149-60.
37. Moore TC, Moore JE, Kaji Y, et al. The role of advanced glycation end products in retinal microvascular leukostasis. Invest Ophthalmol Vis Sci 2003; 44: 4457-64.
38. Blann AD. Assessment of endothelial dysfunction: focus on atherothrombotic disease. Pathophysiol Haemost Thromb 2003; 33: 256-61.
39. Mannarino E, Pirro M. Endothelial injury and repair: a novel theory for atherosclerosis. Angiology 2008; 59: 69S-72S.
40. Pirro M, Schillaci G, Menecali C, et al. Reduced number of circulating endothelial progenitors and HOXA9 expression in CD34+ cells of hypertensive patients. J Hypertens 2007; 25: 2093-9.
41. Pirro M, Schillaci G, Bagaglia F, et al. Microparticles derived from endothelial progenitor cells in patients at different cardiovascular risk. Atherosclerosis 2008; 197: 757-67.
42. Pirro M, Schillaci G, Paltriccia R, et al. Increased ratio of CD31+/CD42-microparticles to endothelial progenitors as a novel marker of atherosclerosis in hypercholesterolemia. Arterioscler Thromb Vasc Biol 2006; 26: 2530-5.
43. Sinning JM, Losch J, Walenta K, et al. Circulating CD31+/ Annexin V+ microparticles correlate with cardiovascular outcomes. Eur Heart J 2011; 32: 2034-41.
44. Schmidt-Lucke C, Rossig L, Fichtlscherer S, et al. Reduced number of circulating endothelial progenitor cells predicts future cardiovascular events: proof of concept for the clinical importance of endogenous vascular repair. Circulation 2005; 111: 2981-7.
45. Soltesz P, Kerekes G, Der H, et al. Comparative assessment of vascular function in autoimmune rheumatic diseases: considerations of prevention and treatment. Autoimmun Rev 2011; 10: 416-25.
46. Ikdahl E, Hisdal J, Rollefstad S, et al. Rosuvastatin improves endothelial function in patients with inflammatory joint diseases, longitudinal associations with atherosclerosis and arteriosclerosis: results from the RORA-AS statin intervention study. Arthritis Res Ther 2015; 17: 279.
47. Schillaci G, Bartoloni E, Pucci G, et al. Aortic stiffness is increased in polymyalgia rheumatica and improves after steroid treatment. Ann Rheum Dis 2012; 71: 1151-6.
48. Pirro M, Bocci EB, Di Filippo F, et al. Imbalance between endothelial injury and repair in patients with polymyalgia rheumatica: improvement with corticosteroid treatment. J Intern Med 2012; 272: 177-84.
49. Strimpakos AS, Sharma RA. Curcumin: preventive and therapeutic properties in laboratory studies and clinical trials. Antioxid Redox Signal 2008; 10: 511-45.
50. Jurenka JS. Anti-inflammatory properties of curcumin, a major constituent of Curcuma longa: a review of preclinical and clinical research. Altern Med Rev 2009; 14: 141-53.
51. Shureiqi I, Baron JA. Curcumin chemoprevention: the long road to clinical translation. Cancer Prev Res (Phila) 2011; 4: 296-8.
52. Basile V FE, Lazzari S, Belluti S, Pignedoli F, Imbriano C. Curcumin derivatives: molecular basis of their anticancer activity. Biochem Pharmacol 2009; 78: 1305-15.
53. Bar-Sela G, Epelbaum R, Schaffer M. Curcumin as an anti-cancer agent: review of the gap between basic and clinical applications. Curr Med Chem 2010; 17: 190-7.
54. Sharma RA, Gescher AJ, Steward WP. Curcumin: the story so far. Eur J Cancer 2005; 41: 1955-68.
55. Brouet I, Ohshima H. Curcumin, an anti-tumour promoter and antiinflammatory agent, inhibits induction of nitric oxide synthase in activated macrophages. Biochem Biophys Res Commun 1995; 206: 533-40.
56. Kang G, Kong PJ, Yuh YJ, et al. Curcumin suppresses lipopolysaccharide-induced cyclooxygenase-2 expression by inhibiting activator protein 1 and nuclear factor kappab bindings in BV2 microglial cells. J Pharmacol Sci 2004; 94: 325-8.
57. Li CJ, Zhang LJ, Dezube BJ, Crumpacker CS, Pardee AB. Three inhibitors of type 1 human immunodeficiency virus long terminal repeat-directed gene expression and virus replication. Proc Natl Acad Sci USA 1993; 90: 1839-42.
58. Sharma OP. Antioxidant activity of curcumin and related compounds. Biochem Pharmacol 1976; 25: 1811-2.
59. Sidhu GS, Mani H, Gaddipati JP, et al. Curcumin enhances wound healing in streptozotocin induced diabetic rats and genetically diabetic mice. Wound Repair Regen 1999; 7: 362-74.
60. Nakmareong S, Kukongviriyapan U, Pakdeechote P, et al. Antioxidant and vascular protective effects of curcumin and tetrahydrocurcumin in rats with L-NAME-induced hypertension. Naunyn Schmiedebergs Arch Pharmacol 2011; 383: 519-29.
61. Castro MM, Rizzi E, Rodrigues GJ, et al. Antioxidant treatment reduces matrix metalloproteinase-2-induced vascular changes in renovascular hypertension. Free Radic Biol Med 2009; 46: 1298-307.
62. Ahuja KD, Kunde DA, Ball MJ, Geraghty DP. Effects of capsaicin, dihydrocapsaicin, and curcumin on copper-induced oxidation of human serum lipids. J Agric Food Chem 2006; 54: 6436-9.
63. Sahebkar A, Serban MC, Gluba-Brzózka A, et al. Lipid-modifying effects of nutraceuticals: An evidence-based approach. Nutrition 2016c; 32: 1179-92.
64. Shehzad A, Lee J, Lee YS. Curcumin in various cancers. Biofactors 2013; 39: 56-68.
65. Park J, Conteas CN. Anti-carcinogenic properties of curcumin on colorectal cancer. World J Gastrointest Oncol 2010; 2: 169-76.
66. Khar A, Ali AM, Pardhasaradhi BV, Begum Z, Anjum R. Antitumor activity of curcumin is mediated through the induction of apoptosis in AK-5 tumor cells. FEBS Lett 1999; 445: 165-8.
67. Panahi Y, Saadat A, Beiraghdar F, Sahebkar A. Adjuvant therapy with bioavailability-boosted curcuminoids suppresses systemic inflammation and improves quality of life in patients with solid tumors: a randomized double-blind placebo-controlled trial. Phytother Res 2014; 28: 1461-7.
68. Panahi Y, Sahebkar A, Parvin S, Saadat A. A randomized controlled trial on the anti-inflammatory effects of curcumin in patients with chronic sulphur mustard-induced cutaneous complications. Ann Clin Biochem 2012; 49: 580-8.
69. Gupta SC, Kim JH, Prasad S, Aggarwal BB. Regulation of survival, proliferation, invasion, angiogenesis, and metastasis of tumor cells through modulation of inflammatory pathways by nutraceuticals. Cancer Metastasis Rev 2010; 29: 405-34.
70. Esmaily H, Sahebkar A, Iranshahi M, et al. An investigation of the effects of curcumin on anxiety and depression in obese individuals: A randomized controlled trial. Chinese J Integrative Med 2015; 21: 332-8.
71. Derosa G, Maffioli P, Sahebkar A. Plasma uric acid concentrations are reduced by fenofibrate: A systematic review and meta-analysis of randomized placebo-controlled trials. Pharmacol Res 2015; 102: 63-70.
72. Sahebkar A, Mohammadi A, Atabati A, et al. Curcuminoids modulate pro_oxidant-antioxidant balance but not the immune response to heat shock protein 27 and oxidized LDL in obese individuals. Phytother Res 2013; 27: 1883-8.
73. Panahi Y, Alishiri GH, Parvin S, Sahebkar A. Mitigation of systemic oxidative stress by curcuminoids in osteoarthritis: Results of a randomized controlled trial. J Dietary Suppl 2015.
74. Panahi Y, Rahimnia AR, Sharafi M, Alishiri G, Saburi A, Sahebkar A. Curcuminoid treatment for knee osteoarthritis: A randomized double_blind placebo_controlled trial. Phytotherapy Research 2014; 28: 1625-31.
75. Ganjali S, Sahebkar A, Mahdipour E, et al. Investigation of the effects of curcumin on serum cytokines in obese individuals: a randomized controlled trial. The Scientific World J 2014; 2014.
76. Panahi Y, Saadat A, Beiraghdar F, Sahebkar A. Adjuvant therapy with bioavailability_boosted curcuminoids suppresses systemic inflammation and improves quality of life in patients with solid tumors: A randomized double-blind placebo-controlled trial. Phytother Res 2014; 28: 1461-7.
77. Panahi Y, Sahebkar A, Parvin S, Saadat A. A randomized controlled trial on the anti-inflammatory effects of curcumin in patients with chronic sulphur mustard-induced cutaneous complications. Ann Clin Biochem 2012; 49: 580-8.
78. Seyedzadeh MH, Safari Z, Zare A, et al. Study of curcumin immunomodulatory effects on reactive astrocyte cell function. Int Immunopharmacol 2014; 22: 230-5.
79. Sankar P, Telang AG, Suresh S, et al. Immunomodulatory effects of nanocurcumin in arsenic-exposed rats. Int Immunopharmacol 2013; 17: 65-70.
80. Sahebkar A, Cicero AF, Simental-Mendia LE, Aggarwal BB, Gupta SC. Curcumin downregulates human tumor necrosis factoralpha levels: A systematic review and meta-analysis ofrandomized controlled trials. Pharmacol Res 2016; 107: 234-42.
81. Yang Y, Wu X, Wei Z, et al. Oral curcumin has anti-arthritic efficacy through somatostatin generation via cAMP/PKA and Ca(2+)/CaMKII signaling pathways in the small intestine. Pharmacol Res 2015; 95-96: 71-81.
82. Kuncha M, Naidu VG, Sahu BD, Gadepalli SG, Sistla R. Curcumin potentiates the anti-arthritic effect of prednisolone in Freund's complete adjuvant-induced arthritic rats. J Pharm Pharmacol 2014; 66: 133-44.
83. Kumar K, Rai AK. Proniosomal formulation of curcumin having anti-inflammatory and anti-arthritic activity in different experimental animal models. Pharmazie 2012; 67: 852-7.
84. Sharma O. Antioxidant activity of curcumin and related compounds. Biochem Pharmacol 1976; 25: 1811-2.
85. Sahebkar A. Molecular mechanisms for curcumin benefits against ischemic injury. Fertil Steril 2010; 94: e75-6; author reply e77.
86. Mohammadi A, Sahebkar A, Iranshahi M, et al. Effects of supplementation with curcuminoids on dyslipidemia in obese patients: a randomized crossover trial. Phytother Res 2013; 27: 374-9.
87. Um MY, Hwang KH, Choi WH, Ahn J, Jung CH, Ha TY. Curcumin attenuates adhesion molecules and matrix metalloproteinase expression in hypercholesterolemic rabbits. Nutr Res 2014; 34: 886-93.
88. Yang YS, Su YF, Yang HW, Lee YH, Chou JI, Ueng KC. Lipidlowering effects of curcumin in patients with metabolic syndrome: a randomized, double-blind, placebo-controlled trial. Phytother Res 2014; 28: 1770-7.
89. Sahebkar A. Are curcuminoids effective C-reactive proteinlowering agents in clinical practice? Evidence from a metaanalysis. Phytother Res 2014; 28: 633-42.
90. Fan C, Wo X, Qian Y, Yin J, Gao L. Effect of curcumin on the expression of LDL receptor in mouse macrophages. J Ethnopharmacol 2006; 105: 251-4.
91. Arafa HM. Curcumin attenuates diet-induced hypercholesterolemia in rats. Med Sci Monit 2005; 11: 228-34.
92. Asai A, Miyazawa T. Dietary curcuminoids prevent high-fat dietinduced lipid accumulation in rat liver and epididymal adipose tissue. J Nutr 2001; 131: 2932-5.
93. Sahebkar A. Curcuminoids for the management of hypertriglyceridaemia. Nat Rev Cardiol 2014; 11: 123.
94. Sahebkar A, Henrotin Y. Analgesic efficacy and safety of curcuminoids in clinical practice: A systematic review and meta-analysis of randomized controlled trials. Pain Med 2016; 17: 1192-202.
95. Sahebkar A, Saboni N, Pirro M, Banach M. Curcumin: An effective adjunct in patients with statin-associated muscle symptoms? J Cachexia Sarcopenia Muscle 2016; doi: 10.1002/jcsm.12140.
96. Sharma S, Kulkarni SK, Chopra K. Curcumin, the active principle of turmeric (Curcuma longa), ameliorates diabetic nephropathy in rats. Clin Exp Pharmacol Physiol 2006; 33: 940-5.
97. Sahebkar A. Dual effect of curcumin in preventing atherosclerosis: the potential role of pro-oxidant-antioxidant mechanisms. Nat Prod Res 2015; 29: 491-2.
98. Sahebkar A. Why it is necessary to translate curcumin into clinical practice for the prevention and treatment of metabolic syndrome? Biofactors 2013; 39: 197-208.
99. Shen LL, Jiang ML, Liu SS, et al. Curcumin improves synaptic plasticity impairment induced by HIV-1gp120 V3 loop. Neural Regen Res 2015; 10: 925-31.
100. Chen K, An Y, Tie L, Pan Y, Li X. Curcumin protects neurons from glutamate-induced excitotoxicity by membrane anchored AKAP79-PKA interaction network. Evid Based Complement Alternat Med 2015; 2015: 706207.
101. Wang BF, Cui ZW, Zhong ZH, et al. Curcumin attenuates brain edema in mice with intracerebral hemorrhage through inhibition of AQP4 and AQP9 expression. Acta Pharmacol Sin 2015; 36: 939-48.
102. Sidhu GS, Singh AK, Thaloor D, et al. Enhancement of wound healing by curcumin in animals. Wound Repair and Regeneration 1998; 6: 167-77.
103. Negi P, Jayaprakasha G, Jagan Mohan Rao L, Sakariah K. Antibacterial activity of turmeric oil: a byproduct from curcumin manufacture. J Agric Food Chem 1999; 47: 4297-300.
104. Jordan W, Drew C. Curcumin--a natural herb with anti-HIV activity. Journal of the National Medical Association 1996; 88: 333.
105. Mahady G, Pendland S, Yun G, Lu Z. Turmeric (Curcuma longa) and curcumin inhibit the growth of Helicobacter pylori, a group 1 carcinogen. Anticancer Res 2001; 22: 4179-81.
106. Kim MK, Choi GJ, Lee HS. Fungicidal property of Curcuma longa L. rhizome-derived curcumin against phytopathogenic fungi in a greenhouse. J Agric Food Chem 2003; 51: 1578-81.
107. Reddy RC, Vatsala PG, Keshamouni VG, Padmanaban G, Rangarajan PN. Curcumin for malaria therapy. Biochem Biophys Res Commun 2005; 326: 472-4.
108. Villegas I, Sanchez-Fidalgo S, Alarcon de la Lastra C. New mechanisms and therapeutic potential of curcumin for colorectal cancer. Mol Nutr Food Res 2008; 52: 1040-61.
109. Sitia S, Tomasoni L, Atzeni F, et al. From endothelial dysfunction to atherosclerosis. Autoimmun Rev 2010; 9: 830-4.
110. Anand P, Kunnumakkara AB, Newman RA, Aggarwal BB. Bioavailability of curcumin: problems and promises. Mol Pharm 2007; 4: 807-18.
111. Kapakos G, Youreva V, Srivastava AK. Cardiovascular protection by curcumin: molecular aspects. Indian J Biochem Biophys 2012; 49: 306-15.
112. Wongcharoen W, Phrommintikul A. The protective role of curcumin in cardiovascular diseases. Int J Cardiol 2009; 133: 145-51.
113. Gupta B, Ghosh B. Curcuma longa inhibits TNF-alpha induced expression of adhesion molecules on human umbilical vein endothelial cells. Int J Immunopharmacol 1999; 21: 745-57.
114. Kunnumakkara AB, Anand P, Aggarwal BB. Curcumin inhibits proliferation, invasion, angiogenesis and metastasis of different cancers through interaction with multiple cell signaling proteins. Cancer Lett 2008; 269: 199-225.
115. Baeuerle PA, Henkel T. Function and activation of NF-kappa B in the immune system. Annu Rev Immunol 1994; 12: 141-79.
116. Ross R. Atherosclerosis--an inflammatory disease. N Engl J Med 1999; 340: 115-26.
117. Barnes PJ, Karin M. Nuclear factor-kappaB: a pivotal transcription factor in chronic inflammatory diseases. N Engl J Med 1997; 336: 1066-71.
118. Matsuzawa A, Ichijo H. Stress-responsive protein kinases in redoxregulated apoptosis signaling. Antioxid Redox Signal 2005; 7: 472-81.
119. Clermont F, Adam E, Dumont JE, Robaye B. Survival pathways regulating the apoptosis induced by tumour necrosis factor-alpha in primary cultured bovine endothelial cells. Cell Signal 2003; 15: 539-46.
120. El-Adawi H, Deng L, Tramontano A, et al. The functional role of the JAK-STAT pathway in post-infarction remodeling. Cardiovasc Res 2003; 57: 129-38.
121. Hirano T, Ishihara K, Hibi M. Roles of STAT3 in mediating the cell growth, differentiation and survival signals relayed through the IL-6 family of cytokine receptors. Oncogene 2000; 19: 2548-56.
122. Kim YS, Ahn Y, Hong MH, et al. Curcumin attenuates inflammatory responses of TNF-alpha-stimulated human endothelial cells. J Cardiovasc Pharmacol 2007; 50: 41-9.
123. Binion DG, Heidemann J, Li MS, Nelson VM, Otterson MF, Rafiee P. Vascular cell adhesion molecule-1 expression in human intestinal microvascular endothelial cells is regulated by PI 3-kinase/Akt/MAPK/NF-kappaB: inhibitory role of curcumin. Am J Physiol Gastrointest Liver Physiol 2009; 297: G259-68.
124. Ogawa H, Binion DG, Heidemann J, Theriot M, et al. Mechanisms of MAdCAM-1 gene expression in human intestinal microvascular endothelial cells. Am J Physiol Cell Physiol 2005; 288: C272-81.
125. Wang J, Dong S. ICAM-1 and IL-8 are expressed by DEHP and suppressed by curcumin through ERK and p38 MAPK in human umbilical vein endothelial cells. Inflammation 2012; 35: 859-70.
126. Chan MM. Inhibition of tumor necrosis factor by curcumin, a phytochemical. Biochem Pharmacol 1995; 49: 1551-6.
127. Coban D, Milenkovic D, Chanet A, et al. Dietary curcumin inhibits atherosclerosis by affecting the expression of genes involved in leukocyte adhesion and transendothelial migration. Mol Nutr Food Res 2012; 56: 1270-81.
128. Kumar A, Dhawan S, Hardegen NJ, Aggarwal BB. Curcumin (Diferuloylmethane) inhibition of tumor necrosis factor (TNF)-mediated adhesion of monocytes to endothelial cells by suppression of cell surface expression of adhesion molecules and of nuclear factor-kappaB activation. Biochem Pharmacol 1998; 55: 775-83.
129. Kim Y, Ahn Y, Hong MH, Park JC, Kang JC. Curcumin attenuates nuclear factor-κB, c-Jun N-terminal kinase and p38 in tumor necrosis factor-α-stimulated endothelial cells. Korean Circ J 2006; 36: 482-9.
130. Lee HS, Lee MJ, Kim H, et al. Curcumin inhibits TNFalphainduced lectin-like oxidised LDL receptor-1 (LOX-1) expression and suppresses the inflammatory response in human umbilical vein endothelial cells (HUVECs) by an antioxidant mechanism. J Enzyme Inhib Med Chem 2010; 25: 720-9.
131. Lemasters JJ, Thurman RG. Reperfusion injury after liver preservation for transplantation. Annu Rev Pharmacol Toxicol 1997; 37: 327-38.
132. Roberts JR, Rowe PA, Demaine AG. Activation of NF-kappaB and MAP kinase cascades by hypothermic stress in endothelial cells. Cryobiology 2002; 44: 161-9.
133. Kokura S, Yoshida N, Yoshikawa T. Anoxia/reoxygenationinduced leukocyte-endothelial cell interactions. Free Radic Biol Med 2002; 33: 427-32.
134. Stansby G, Fuller B, Jeremy J, Cheetham K, Rolles K. Endothelin release--a facet of reperfusion injury in clinical liver transplantation? Transplantation 1993; 56: 239-40.
135. Fuller B, Dijk S, Butler P, Hoang V, Davidson B. Proinflammatory agents accumulate during donor liver cold preservation: a study on increased adhesion molecule expression and abrogation by curcumin in cultured endothelial cells. Cryobiology 2003; 46: 284-8.
136. GH Van Zanten PDG, JJ Sixma. Platelets and their factors. Springer 1997: 61-81.
137. Cines DB, Pollak ES, Buck CA, et al. Endothelial cells in physiology and in the pathophysiology of vascular disorders. Blood 1998; 91: 3527-61.
138. Zhang L, Gu ZL, Qin ZH, Liang ZQ. Effect of curcumin on the adhesion of platelets to brain microvascular endothelial cells in vitro. Acta Pharmacol Sin 2008; 29: 800-7.
139. Wang NP, Pang XF, Zhang LH, Tootle S, Harmouche S, Zhao ZQ. Attenuation of inflammatory response and reduction in infarct size by postconditioning are associated with downregulation of early growth response 1 during reperfusion in rat heart. Shock 2014; 41: 346-54.
140. Kim G, Jang MS, Son YM, et al. Curcumin inhibits CD4(+) T cell activation, but augments CD69 expression and TGF-beta1-mediated generation of regulatory T cells at late phase. PLoS One 2013; 8: e62300.
141. Kam A, Li KM, Razmovski-Naumovski V, et al. Curcumin reduces tumour necrosis factor-enhanced annexin V-Positive microparticle release in human vascular endothelial cells. J Pharm Pharm Sci 2015; 18: 424-33.
142. Soares MP, Seldon MP, Gregoire IP, et al. Heme oxygenase-1 modulates the expression of adhesion molecules associated with endothelial cell activation. J Immunol 2004; 172: 3553-63.
143. Motterlini R, Foresti R, Bassi R, Green CJ. Curcumin, an antioxidant and anti-inflammatory agent, induces heme oxygenase-1 and protects endothelial cells against oxidative stress. Free Radic Biol Med 2000; 28: 1303-12.
144. Olszanecki R, Gebska A, Korbut R. The role of haem oxygenase-1 in the decrease of endothelial intercellular adhesion molecule-1 expression by curcumin. Basic Clin Pharmacol Toxicol 2007; 101: 411-5.
145. Boonla O, Kukongviriyapan U, Pakdeechote P, et al. Curcumin improves endothelial dysfunction and vascular remodeling in 2K-1C hypertensive rats by raising nitric oxide availability and reducing oxidative stress. Nitric Oxide 2014; 42: 44-53.
146. Wongeakin N, Bhattarakosol P, Patumraj S. Molecular mechanisms of curcumin on diabetes-induced endothelial dysfunctions: Txnip, ICAM-1, and NOX2 expressions. Biomed Res Int 2014; 2014: 161346.
147. Jung HS, Park KH, Cho YM, et al. Resistin is secreted from macrophages in atheromas and promotes atherosclerosis. Cardiovasc Res 2006; 69: 76-85.
148. Kawanami D, Maemura K, Takeda N, et al. Direct reciprocal effects of resistin and adiponectin on vascular endothelial cells: a new insight into adipocytokine-endothelial cell interactions. Biochem Biophys Res Commun 2004; 314: 415-9.
149. Kunnari AM, Savolainen ER, Ukkola OH, Kesaniemi YA, Jokela MA. The expression of human resistin in different leucocyte lineages is modulated by LPS and TNFalpha. Regul Pept 2009; 157: 57-63.
150. Manduteanu I, Pirvulescu M, Gan AM, et al. Similar effects of resistin and high glucose on P-selectin and fractalkine expression and monocyte adhesion in human endothelial cells. Biochem Biophys Res Commun 2010; 391: 1443-8.
151. Schulz C, Schafer A, Stolla M, et al. Chemokine fractalkine mediates leukocyte recruitment to inflammatory endothelial cells in flowing whole blood: a critical role for P-selectin expressed on activated platelets. Circulation 2007; 116: 764-73.
152. Pirvulescu MM, Gan AM, Stan D, et al. Curcumin and a Morus alba extract reduce pro-inflammatory effects of resistin in human endothelial cells. Phytother Res 2011; 25: 1737-42.
153. Silverstein RL, Nachman RL. Angiogenesis and atherosclerosis. The mandate broadens. Circulation 1999; 100: 783-5.
154. Moreno PR, Purushothaman KR, Sirol M, Levy AP, Fuster V. Neovascularization in human atherosclerosis. Circulation 2006; 113: 2245-52.
155. Falchook GS, Naing A, Hong DS, et al. Dual EGFR inhibition in combination with anti-VEGF treatment: a phase I clinical trial in non-small cell lung cancer. Oncotarget 2013; 4: 118-27.
156. Koch S, Tugues S, Li X, Gualandi L, Claesson-Welsh L. Signal transduction by vascular endothelial growth factor receptors. Biochem J 2011; 437: 169-83.
157. Sreepriya M, Bali G. Chemopreventive effects of embelin and curcumin against N-nitrosodiethylamine/phenobarbital-induced hepatocarcinogenesis in Wistar rats. Fitoterapia 2005; 76: 549-55.
158. Wang F, He Z, Dai W, et al. The role of the vascular endothelial growth factor/vascular endothelial growth factor receptors axis mediated angiogenesis in curcumin-loaded nanostructured lipid carriers induced human HepG2 cells apoptosis. J Cancer Res Ther 2015; 11: 597-605.
159. Binion DG, Otterson MF, Rafiee P. Curcumin inhibits VEGFmediated angiogenesis in human intestinal microvascular endothelial cells through COX-2 and MAPK inhibition. Gut 2008; 57: 1509-17.
160. Gao JZ, Du JL, Wang YL, Li J, Wei LX, Guo MZ. Synergistic effects of curcumin and bevacizumab on cell signaling pathways in hepatocellular carcinoma. Oncol Lett 2015; 9: 295-99.
161. Bimonte S, Barbieri A, Palma G, et al. Dissecting the role of curcumin in tumour growth and angiogenesis in mouse model of human breast cancer. Biomed Res Int 2015; 2015: 878134.
162. Vyas D, Gupt S, Dixit V, Anita K, Kaur S. To study the effect of curcumin on the growth properties of circulating endothelial progenitor cells. In Vitro Cell Dev Biol Anim 2015; 51: 488-94.
163. Kant V, Gopal A, Kumar D, et al. Curcumin-induced angiogenesis hastens wound healing in diabetic rats. J Surg Res 2015; 193: 978-88.
164. Chen D, Tao X, Wang Y, et al. Curcumin accelerates reendothelialization and ameliorates intimal hyperplasia in balloon-injured rat carotid artery via the upregulation of endothelial cell autophagy. Int J Mol Med 2015; 36: 1563-71.
165. Vlachopoulos C, Aznaouridis K, Stefanadis C. Prediction of cardiovascular events and all-cause mortality with arterial stiffness: a systematic review and meta-analysis. J Am Coll Cardiol 2010; 55: 1318-27.
166. Lakatta EG, Levy D. Arterial and cardiac aging: major shareholders in cardiovascular disease enterprises: Part I: aging arteries: a "set up" for vascular disease. Circulation 2003; 107: 139-46.
167. Fleenor BS, Sindler AL, Marvi NK, et al. Curcumin ameliorates arterial dysfunction and oxidative stress with aging. Exp Gerontol 2013; 48: 269-76.
168. Thijssen DH, Black MA, Pyke KE, et al. Assessment of flowmediated dilation in humans: a methodological and physiological guideline. Am J Physiol Heart Circ Physiol 2011; 300: H2-12.
169. Gates PE BM, Silver AE, Monahan KD, Seals DR. Impaired flowmediated dilation with age is not explained by L-arginine bioavailability or endothelial asymmetric dimethylarginine protein expression. J Appl Physiol 2007; 102: 63-71.
170. Gavin KM, Seals DR, Silver AE, Moreau KL. Vascular endothelial estrogen receptor alpha is modulated by estrogen status and related to endothelial function and endothelial nitric oxide synthase in healthy women. J Clin Endocrinol Metab 2009; 94: 3513-20.
171. Yoshizawa M, Maeda S, Miyaki A, et al. Additive beneficial effects of lactotripeptides intake with regular exercise on endothelium-dependent dilatation in postmenopausal women. Am J Hypertens 2010; 23: 368-72.
172. Akazawa N, Choi Y, Miyaki A, et al. Curcumin ingestion and exercise training improve vascular endothelial function in postmenopausal women. Nutr Res 2012; 32: 795-9.
173. He ZY, Shi CB, Wen H, Li FL, Wang BL, Wang J. Upregulation of p53 expression in patients with colorectal cancer by administration of curcumin. Cancer Invest 2011; 29: 208-13.
174. Sugawara J, Akazawa N, Miyaki A, et al. Effect of endurance exercise training and curcumin intake on central arterial hemodynamics in postmenopausal women: pilot study. Am J Hypertens 2012; 25: 651-6.
175. Banach M, Aronow WS, Serban C, et al. Lipids, blood pressure and kidney update 2014. Pharmacol Res 2015; 95-96: 111-25.
176. Sahebkar A, Watts GF. New therapies targeting apoB metabolism for high-risk patients with inherited dyslipidaemias: what can the clinician expect? Cardiovasc Drugs Ther 2013; 27: 559-67.
177. Sahebkar A, Watts GF. New LDL-cholesterol lowering therapies: pharmacology, clinical trials, and relevance to acute coronary syndromes. Clin Ther 2013; 35: 1082-98.
178. Sahebkar A, Chew GT, Watts GF. Recent advances in pharmacotherapy for hypertriglyceridemia. Prog Lipid Res 2014; 56: 47-66.